|
KMID : 0355620100360030177
|
|
Journal of Korean Association of Oral and Maxillofacial Surgeons
2010 Volume.36 No. 3 p.177 ~ p.185
|
|
|
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody and DNA topoisomerase inhibitor reduce growth of salivary adenoid cystic carcinoma in a murine model
|
|
Park Young-Wook
Lee Hee-Su
|
|
|
Abstract
|
|
|
Introduction: Epidermal growth factor receptor (EGFR) is expressed in human epithelial tumors including salivary cancers, and known to be correlated with tumor progression and poor clinical courses in some epithelial tumors. In this study, we determined the therapeutic effect of the anti-EGFR monoclonal antibody Erbitux (C225, cetuximab) in combination with the DNA topoisomerase I inhibitor irinotecan (CPT-11) on human salivary adenoid cystic carcinoma (SACC) cells growing in nude mice.
Materials and Methods: At first, immunocytochemical analysis for the expression of EGFR and phosphorylated EGFR (pEGFR) on a human salivary ACC cell line (ACC3). To determine the in vivo effects of Erbitux and CPT-11, nude mice with orthotopic parotid tumors were randomized to receive intraperitoneal Erbitux (1 ㎎) two times per week, intraperitoneal Irinotecan (50 ㎎/㎏) once per week, Erbitux plus CPT-11, or placebo. (control) Tumor volume and weight were measured. And mechanisms of in vivo activity of Erbitux and/or CPT-11 were determined by immunohistochemical/immunofluorescent analyses.
Results: Immunocytochemical staining of ACC3 demonstrated that EGFR was expressed and phosphorylated. CPT-11 inhibited ACC tumor growth in nude mice. Tumors of mice treated with CPT-11 and CPT-11 plus Erbitux exhibited increased tumor cell apoptosis and decreased microvessel density, which correlated with a decrease in the tumor volume in nude mice. But, CPT-11 seems not to be synergistic with Erbitux in our ACC3 model system.
Conclusion: These results suggest that anti-EGFR monoclonal antibody and the DNA topoisomerase I inhibitor will be effective in the treatment of recurred or metastatic lesions of salivary ACC.
|
|
|
KEYWORD
|
|
|
Monoclonal antibodies, Epidermal growth factor receptor, DNA topoisomerases type 1, Adenoid cystic carcinoma, Salivary gland neoplasms, Parotid neoplasms
|
|
|
FullTexts / Linksout information
|
|
  
|
|
|
Listed journal information
|
|
 
|
|